Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.

Programmed death ligand-1 expression in non-small cell lung cancer.

Author information

  • 1Solid Tumor, Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • 2Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
  • 3Department of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
  • 41] Department of Medical Oncology, Yale School of Medicine, New Haven, CT, USA [2] Oncology Unit, Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece.
  • 51] Department of Medical Oncology, Yale School of Medicine, New Haven, CT, USA [2] Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.

Abstract

Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials. In this study, we used various antibodies and in situ mRNA hybridization to measure PD-L1 in non-small cell lung cancer (NSCLC) using a quantitative fluorescence (QIF) approach to determine the frequency of expression and prognostic value in two independent populations. A control tissue microarray (TMA) was constructed using PD-L1-transfected cells, normal human placenta and known PD-L1-positive NSCLC cases. Only one of four antibodies against PD-L1 (5H1) validated for specificity on this TMA. In situ PD-L1 mRNA using the RNAscope method was similarly validated. Two cohorts of NSCLC cases in TMAs including 340 cases from hospitals in Greece and 204 cases from Yale University were assessed. Tumors showed PD-L1 protein expression in 36% (Greek) and 25% (Yale) of the cases. PD-L1 expression was significantly associated with tumor-infiltrating lymphocytes in both cohorts. Patients with PD-L1 (both protein and mRNA) expression above the detection threshold showed statistically significant better outcome in both series (log-rank P=0.036 and P=0.027). Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology. Measurement of PD-L1 requires specific conditions and some commercial antibodies show lack of specificity. Expression of PD-L1 protein or mRNA is associated with better outcome. Further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.

PMID:
24217091
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk